Download CT - STN International

L’OFFRE BIOMEDICALE
Martine MICHEL
[email protected]
CAPADOC
Agenda
• L’offre STN
– contenu
– fonctionnalités principales
• Les banques de données biomédicales
– thésaurus
– recherche multifichiers
• Les alertes
L’offre STN
• Accès à une vaste collection internationale
d’informations scientifiques et techniques (plus de
120 banques de données)
• incluant de multiples banques de données
biomédicales et pharmaceutiques
ADISCTI ADISINSIGHT ADISNEWS BIOENG BIOSIS
BIOTECHNO CAPLUS DDFB DDFU DRUGB DRUGU
EMBAL EMBASE ESBIOBASE IMSPATENTS IMSRESEARCH
IPA KOSMET LIFESCI MEDLINE NAPRALERT PASCAL
RTECS SCISEARCH TOXCENTER USAN
Plus de détails, en consultant les fiches techniques (Database summary sheets)
Effectuer une recherche en ligne
• Les commandes de base
FILE
(FIL)
CHOIX D'UNE BANQUE DE DONNÉES
EXPAND
(E, EXP)
VERIFICATION DE LA PRESENCE D'UN TERME
DANS UN INDEX ALPHABETIQUE
SEARCH
(S, SEA)
RECHERCHE DE TERMES
DISPLAY
(D, DIS)
VISUALISATION DES RÉFÉRENCES OBTENUES
LOGOFF
(LOG)
DECONNEXION
Paramétrage du loginid :
SET PLURALS ON PERM
pour une recherche automatique des pluriels
SET SPELLINGS ON PERM
pour une recherche automatique des termes Us/Gb
SET AUTOSEARCH ON PERM pour ne pas taper la commande “Search”
Recherche thématique
• La recherche textuelle (par mots, par
descripteurs, par n° Cas) s’effectue, par défaut,
dans le titre, le résumé et l’indexation qui
constituent l’index de base (Basic Index)
Basic
Index
Title
Abstract
Indexing
terms
Les opérateurs
• Les opérateurs booléens : AND, OR, NOT
• Les opérateurs de proximité
Symboles de troncature
Symbole
?
#
!
Remplace
Recherche
Termes retrouvés
0 ou n caractère
S VACCIN?
VACCIN
VACCINS
VACCINATION
VACCINAL
S ?TOXIC?
TOXIC
TOXICITY
CYTOTOXIC
CARDIOTOXIC
S CATECHIN##
CATECHIN
CATECHINS
CATECHINE
CATECHINES
S #ESTROGEN
ESTROGEN
OESTROGEN
S BI!ALM
BIKALM
BICALM
0 ou 1 caractère
1 caractère
Lancement de la recherche
=> FILE EMBASE
=> S YTTRIUM (A) 90 AND (HEPAT? OR LIVER)(W)(CARCINO? OR CANCER? OR
NEOPLASM?)
6883 YTTRIUM
398101 90
1170 YTTRIUM (A) 90
528633 HEPAT?
803061 LIVER
32753 LIVERS
805556 LIVER
(LIVER OR LIVERS)
686146 CARCINO?
924965 CANCER?
1918201 NEOPLASM?
122447 (HEPAT? OR LIVER)(W)(CARCINO? OR CANCER? OR
NEOPLASM?)
L1
305 YTTRIUM (A) 90 AND (HEPAT? OR LIVER)(W)(CARCINO? OR
CANCER? OR NEOPLASM?)
L1 est l’étape résultat
contenant 305 références
Visualisation des références
=> D ALL
L1
AN
TI
AU
CS
B
I
B
AU
CS
AU
CS
AU
CS
SO
CY
DT
Informations
ANSWER 1 OF 305
EMBASE on STN
bibliographiques
2013013197 EMBASE
Yttrium-90 radioembolization for the treatment of unresectable
hepatocellular carcinoma in patients with transjugular intrahepatic
portosystemic shunts.
Donahue, Laurence A.; Gupta, Ramona; Memon, Khairuddin; Salem, Riad;
Lewandowski, Robert J., Dr. (correspondence)
Department of Radiology, Section of Interventional Radiology, United
States. [email protected]
Salem, Riad
Department of Medicine, Division of Hematology and Oncology, United
States.
Kulik, Laura; Ganger, Daniel R.
Department of Medicine, Division of Hepatology, United States.
Baker, Talia; Abecassis, Michael M.
Department of Transplant Surgery, Northwestern Memorial Hospital,
Robert H. Lurie Comprehensive Cancer Center, 676 N. St. Clair Street,
Chicago, IL 60611, United States.
Journal of Vascular and Interventional Radiology, (January 2013) Vol.
24, No. 1, pp. 74-80.
Refs: 40
ISSN: 1051-0443; E-ISSN: 1535-7732 CODEN: JVIRE3
United States
Journal; Article
FS
LA
SL
ED
AB
A
B
S
016
Cancer
023
Nuclear Medicine
037
Drug Literature Index
038
Adverse Reactions Titles
048
Gastroenterology
English
English
Entered STN: 21 Jan 2013
Résumé
Last Updated on STN: 21 Jan 2013
Purpose: To evaluate the toxicity and response to radioembolization with
yttrium-90 (90Y) glass microspheres in patients with hepatocellular
carcinoma (HCC) and existing transjugular intrahepatic portosystemic
shunts (TIPS). Materials and Methods: For treatment of unresectable HCC,
12 patients with a patent TIPS underwent a total of 21 infusions of 90Y.
Toxicity within 90 days of treatment was assessed according to the
National Cancer Institute Common Terminology Criteria for Adverse Events
(CTCAE v4.0). Imaging response within the index lesion was assessed
using the World Health Organization (WHO) and European Association for
the Study of the Liver (EASL) guidelines. Survival was calculated using
the Kaplan-Meier method. Results: All patients had a patent TIPS on
imaging before treatment. Clinical toxicities included fatigue (83%),
encephalopathy (33%), and abdominal pain (25%). Three patients (25%)
experienced new grade 3 or 4 bilirubin toxicity. Imaging response was
achieved in 50% and 67% of patients according to WHO and EASL criteria.
Six patients (50%) went on to liver transplantation. Median survival
censored for liver transplantation was 498 days (95% confidence interval
[CI],100-800 d), and uncensored median survival was 827 days (95% CI,
250-2,400 d).°°°°°
CT
I
N
D
CT
RN
Medical Descriptors:
abdominal pain
adult
article
*artificial embolism
brain disease
cancer patient
*cancer radiotherapy
cancer survival
clinical article
drug efficacy
drug safety
fatigue: SI, side effect
female
human
*liver cell carcinoma: DT, drug therapy
*liver cell carcinoma: RT, radiotherapy
*liver cell carcinoma: SU, surgery
liver transplantation
male
radiation injury
*radioembolization
*transjugular intrahepatic portosystemic shunt
treatment response
Drug Descriptors:
*yttrium 90: AE, adverse drug reaction
*yttrium 90: DT, drug therapy
(yttrium 90) 10098-91-6
Vocabulaire
contrôlé
Visualisation des références
• La commande Display permet de visualiser
les références obtenues
• Spécifier
– Le numéro d’étape (par défaut, la dernière)
– Le numéro d’ordre des références (par défaut, la première)
– Le format de visualisation (par défaut, BIB)
• BIB
infos bibliographiques
• ABS
résumé
• IND
indexation
• ALL
format complet (BIB+ABS+IND)
• TI AU
titre et auteur
L‘offre biomédicale sur STN
• MEDLINE (1946-)
– Contient les références in-process
• EMBASE (1947-)
– EMBAL (Embase Alert Database)
• BIOSIS (1926-)
• DDFU (Derwent Drug file, 1983-)
– DDFB (Derwent Drug back file, 1964-)
• ADISNEWS (inclut Reactions, 1983-)
L‘offre biomédicale sur STN
• IPA ( International Pharmaceutical Abstracts, 1970-)
• ADISCTI (Adis Clinical Trials Insight, 1998-)
• HCAPLUS (Chemical Abstracts, 1907-)
• TOXCENTER (1907-)
(Biosis, Caplus, Medline, Ipa + 14 fcihiers gouvernementaux américains)
• PASCAL (1977-)
• SCISEARCH (Science Citation Index, 1974-)
Thésaurus
• Liste hiérarchisée de descripteurs (Controlled Terms)
– Broader Term (BT) : terme générique
– Narrower Term (NT) : terme spécifique
Narrower Terms
Broader Term (BT)
Term
NT1
NT1
NT
2
NT
2
Term
NT1
NT
2
NT
2
NT1
NT
2
NT
2
NT1
NT
2
Term
NT1
NT
2
NT
2
NT1
NT1
NT
2
NT
2
• MeSH, thésaurus de MEDLINE (NLM -US)
– ~25000 descripteurs (Subject Headings)
• Qualificatifs (qualifiers)
• ~170000 synonymes (Entry Terms )
– Révision annuelle
• EMTREE, thésaurus de EMBASE (Elsevier - NL)
– ~58000 descripteurs (Preferred Terms)
• dont 28000 noms de médicaments, substances chimiques
– >20000 n° CAS Registry
• Qualificatifs (Link Terms)
• ~240000 synonymes
– incluant tous les noms génériques utilisés par FDA et
EMEA, tous les WHO INNs depuis 2000, les principaux
noms commerciaux, les termes MeSH
– Révision annuelle
La commande EXPAND
• EXPAND permet de visualiser les termes interrogeables
dans un index spécifique
• Par défaut, 12 termes sont visualisés (max 999)
• Taper à nouveau E pour poursuivre la liste
=> E ENGLISH/LA
E1
17761243
E2
17761243
E3
17761243 -->
E4
178
E5
92583
E6
178
E7
410
E8
410
E9
122
E10
5691
E11
4288
E12
4288
EN/LA
ENG/LA
ENGLISH/LA
EO/LA
ES/LA
ESPERANTO/LA
ESTONIAN/LA
ET/LA
EU/LA
FA/LA
FI/LA
FINNISH/LA
=> S L1 AND ENGLISH/LA
OU
=> S L1 AND E3
• => SET EXPAND CONTINUOUS PERM : numérotation en continu des E#
Vocabulaire contrôlé (Controlled Term)
Frequency : nombre de documents indexés avec
ce descripteur
=> FILE EMBASE
=> E BETA ADRENERGIC RECEPTOR/CT
E#
-E1
E2
FREQUENCY
--------1
0
E3
24088
E4
E5
E6
E7
E8
E9
E10
E11
E12
5
4
8
7
3
3
0
0
0
AT
-2
AT (Associated Term) : nombre de termes
associés (BT, NT)
TERM
---BETA ADRENERGIC PARTIAL AGONIST: PD, PHARMACOLOGY/CT
BETA ADRENERGIC RECEPTION/CT
24 --> BETA ADRENERGIC RECEPTOR/CT
2
2
2
BETA
BETA
BETA
BETA
BETA
BETA
BETA
BETA
BETA
ADRENERGIC
ADRENERGIC
ADRENERGIC
ADRENERGIC
ADRENERGIC
ADRENERGIC
ADRENERGIC
ADRENERGIC
ADRENERGIC
RECEPTOR
RECEPTOR
RECEPTOR
RECEPTOR
RECEPTOR
RECEPTOR
RECEPTOR
RECEPTOR
RECEPTOR
1/CT
1: EC, ENDOGENOUS COMPOUND/CT
2/CT
2: EC, ENDOGENOUS COMPOUND/CT
3/CT
3: EC, ENDOGENOUS COMPOUND/CT
AGENT/CT
AGONIST/CT
ANTAGONIST/CT
Vocabulaire contrôlé (Controlled Term)
=> E E3+ALL
E15
4
E16
26
E17
42
derivatives/CT
E18
839
E19
595
E20
24262
E21
394
E22
8967
E23
24088
E24
E25
E26
E27
E28
E29
E30
0
0
0
0
0
0
0
+ALL pour ouvrir le thésaurus
BT8
emtree thesaurus/CT
BT7
chemicals and drugs/CT
BT6
natural products and their synthetic
BT5
peptides and proteins/CT
BT4
carrier proteins and binding proteins/CT
BT3
receptor/CT
BT2
catecholamine receptor/CT
BT1
adrenergic receptor/CT
-->
beta adrenergic receptor/CT
HNTE Creation date 01 JAN 1974
UF
UF
UF
UF
UF
UF
UF
adrenalin receptor/CT
adrenergic beta receptor/CT
beta adrenergic nervous system/CT
beta adrenergic reception/CT
beta adrenoceptor/CT
UF (Used For) : synonymes
beta adrenoreceptor/CT
beta adrenotropic receptor/CT
Vocabulaire contrôlé (Controlled Term)
E31
0
E32
0
E33
0
E34
0
E35
0
E36
4064
E37
7509
E38
1872
********** END **********
UF
UF
UF
UF
UF
NT1
NT1
NT1
beta receptor/CT
beta sympathetic receptor/CT
epinephrine receptor/CT
receptor,beta adrenergic/CT
receptors, adrenergic, beta/CT
beta 1 adrenergic receptor/CT
beta 2 adrenergic receptor/CT
beta 3 adrenergic receptor/CT
NT (Narrower Term) : descripteur spécifique
=> S BETA ADRENERGIC RECEPTOR+NT/CT
L1
33652 BETA ADRENERGIC RECEPTOR+NT/CT
(4 TERMS)
Vocabulaire contrôlé (Controlled Term)
=> E ZOCOR/CT 5
E#
FREQUENCY
---------E1
1
E2
5
E3
0
E4
2
E5
19
AT
--
TERM
---ZOCLOPENTHIXOL: DT, DRUG THERAPY/CT
ZOCON/CT
2 --> ZOCOR/CT
2
ZOCOR FORTE/CT
ZOCOR HEART PRO/CT
„Zocor“ n‘est pas le descripteur officiel mais il existe un descripteur
=> E E3+ALL
E6
0
E7
21477
-->
USE
=> E E7+ALL
E8
4
E9
26
E10
123
E11
83
E12
4
E13
26
BT7
emtree thesaurus/CT
BT6
chemicals and drugs/CT
BT5
agents affecting metabolism/CT
BT4
agents affecting lipid metabolism/CT
BT6
emtree thesaurus/CT
BT5
chemicals and drugs/CT
zocor/CT
simvastatin/CT
Vocabulaire contrôlé (Controlled Term)
°°
E23
E24
E25
E26
E27
E28
E29
E30
E31
E32
E33
°°°
21477
0
0
2
0
0
1
0
0
0
0
-->
simvastatin/CT
HNTE Creation date 01 JAN 1986
RN
79902-63-9
UF
avastinee/CT
UF
cholestat/CT
UF
clinfar/CT
UF
colastatina/CT
UF
colestricon/CT
UF
covastin/CT
UF
denan/CT
UF
epistatin/CT
UF
esvat/CT
UF
ethicol/CT
E78
0
UF
E79
1
UF
E80
0
UF
E81
2
UF
E82
0
UF
E83
0
UF
********** END **********
vidastat/CT
zimmex/CT
zocor/CT
zocor forte/CT
zocord/CT
zovast/CT
Vocabulaire contrôlé (Controlled Term)
=> S SIMVASTATIN/CT
L1
21477 SIMVASTATIN/CT
=> D TI KWIC 1-2
L1
ANSWER 1 OF 21477 EMBASE COPYRIGHT (c) 2012 Elsevier B.V. All
rights reserved on STN
TI
Pleiotropic effects of pitavastatin.
CT
Medical Descriptors:
article
atherosclerosis: . . .
rosuvastatin: CM, drug comparison
rosuvastatin: IT, drug interaction
rosuvastatin: PK, pharmacokinetics
rosuvastatin: PD, pharmacology
simvastatin: AN, drug analysis
simvastatin: CM, drug comparison
simvastatin: PK, pharmacokinetics
simvastatin: PD, pharmacology
triacylglycerol: EC, endogenous compound
Descripteurs principaux
L1
ANSWER 2 OF 21477
rights reserved on STN
TI
CT
EMBASE
COPYRIGHT (c) 2012 Elsevier B.V. All
Effects of 4-week administration of simvastatin in different
doses on heart rate and blood pressure after metoprolol
injection in normocholesterolaemic and normotensive rats.
Medical Descriptors:
animal . . .
cholesterol: EC, endogenous compound
methylcellulose
*metoprolol: CB, drug combination
*metoprolol: IP, intraperitoneal drug administration
*simvastatin: CB, drug combination
*simvastatin: IG, intragastric drug administration
triacylglycerol: EC, endogenous compound
Les descripteurs principaux (Major Concepts) sont précédés d’une étoile.
=> S L1/MAJ
L2
6183 S L1/MAJ
ou
S *SIMVASTATIN/CT
EMBASE : qualificatifs (Link-Terms)
DRUG LINKS
---------adverse drug reaction
clinical trial
drug administration
drug analysis
drug combination
drug comparison
drug concentration
drug development
drug dose
drug interaction
drug therapy
drug toxicity
endogenous compound
pharmaceutics
pharmacoeconomics
pharmacokinetics
pharmacology
CODE
---AE
CT
AD
AN
CB
CM
CR
DV
DO
IT
DT
TO
EC
PR
PE
PK
PD
DISEASE LINKS
-----------complication
congenital disorder
diagnosis
disease management
drug resistance
drug therapy
epidemiology
etiology
prevention
radiotherapy
rehabilitation
side effect
surgery
therapy
CODE
---CO
CN
DI
DM
DR
DT
EP
ET
PC
RT
RH
SI
SU
TH
+ 47 additional "routes of drug administration links"
MEDLINE : qualificatifs (qualifiers)
http://www.nlm.nih.gov/mesh/MBrowser.html
Les qualificatifs
=> S *SIMVASTATIN/CT (L) (AE OR TO)
L1
1311 *SIMVASTATIN/CT (L) (AE OR TO)
L’opérateur de proximité (L) sert à
=> D BIB KWIC
qualificatif
au descripteur
L1
ANSWER 1 OF 1311 EMBASE COPYRIGHT relier
(c) le
2012
Elsevier
B.V. All
rights reserved on STN
AN
2012131597 EMBASE
TI
Simvastatin disrupts cytoskeleton and decreases cardiac
fibroblast adhesion, migration and viability.
AU
Copaja, Miguel; Venegas, Daniel; Aranguiz, Pablo; Canales,
Jimena; Vivar, Raul; Avalos, Yennifer; Garcia, Lorena; Chiong,
Mario; Olmedo, Ivonne; Catalan, Mabel; Leyton, Lisette;
Lavandero, Sergio; Diaz-Araya, Guillermo (correspondence)
CS
Centro Estudios Moleculares de la Celula, Facultad Ciencias
Quimicas y Farmaceuticas, Universidad de Chile, Santiago,
Chile. [email protected]
AU
Leyton, Lisette; Lavandero, Sergio
CS
Instituto de Ciencias Biomedicas, Facultad Medicina,
Universidad de Chile, Santiago, Chile.
AU
Lavandero, Sergio
CS
Department of Internal Medicine (Cardiology Division),
University of Texas Southwestern Medical Center, Dallas, TX,
United States.
SO
PB
PUI
CY
DT
FS
LA
SL
ED
CT
Toxicology, (29 Mar 2012) Vol. 294, No. 1, pp. 42-49.
Refs: 44
ISSN: 0300-483X; E-ISSN: 1879-3185 CODEN: TXCYAC
Elsevier Ireland Ltd, P.O. Box 85, Limerick, Ireland.
S 0300-483X(12)00021-2
Ireland
Journal; Article
018
Cardiovascular Diseases and Cardiovascular Surgery
029
Clinical and Experimental Biochemistry
037
Drug Literature Index
052
Toxicology
English
English
Entered STN: 13 Mar 2012
Last Updated on STN: 13 Mar 2012
Medical Descriptors:
actin . . .
EC, endogenous compound
collagen: EC, endogenous compound
isoprenoid: PD, pharmacology
paxillin: EC, endogenous compound
*simvastatin: TO, drug toxicity
vimentin: EC, endogenous compound
vinculin: EC, endogenous compound
Les limites
EMBASE
MEDLINE
ANIMAL
/NON
/ANI
HUMAN
/HUM
/HUM
FEMALE
/FEM
/FEM
MALE
/MAL
/MAL
ENGLISH LANGUAGE
/ENG
/ENG
MAJOR CONCEPT
/MAJ
/MAJ
=> S SIMVASTATIN/CT
L1
21483 SIMVASTATIN/CT
=> S L1/MAJ,HUM
L2
4926 L1/MAJ,HUM
Les limites
par tranche d‘âge
=> FILE MEDLINE
=> E AGE GROUPS+NT/CT
E2
E3
E4
E5
E6
E7
E8
E9
E10
E11
E12
E13
E14
E15
E16
E17
E18
E19
E20
0
6359239
1445450
3549638
2043054
507991
5551
2935628
198673
1247215
684869
586828
456611
13981
4466
5118
757
230
36937
-->
Age Groups/CT
MN
M1.60./CT
NT1
Adolescent/CT
NT1
Adult/CT
NT2
Aged/CT
NT3
Aged, 80 and over/CT
NT3
Frail Elderly/CT
NT2
Middle Aged/CT
NT2
Young Adult/CT
NT1
Child/CT
NT2
Child, Preschool/CT
NT1
Infant/CT
NT2
Infant, Newborn/CT
NT3
Infant, Low Birth Weight/CT
NT4
Infant, Small for Gestational Age/CT
NT4
Infant, Very Low Birth Weight/CT
NT5
Infant, Extremely Low Birth Weight/CT
NT3
Infant, Postmature/CT
NT3
Infant, Premature/CT
Les limites
par tranche d‘âge
=> FILE EMBASE
=> E GROUPS BY AGE+NT/CT
E21
E22
E23
E24
E25
E26
E27
E28
E29
E30
34797
1956947
311
3762
690
170267
160378
951697
469970
6298
-->
groups by age/CT
NT1
aged/CT
NT2
aged hospital patient/CT
NT2
frail elderly/CT
NT2
very elderly/CT
NT1
embryo/CT
NT1
fetus/CT
NT1
middle aged/CT
NT1
newborn/CT
NT2
suckling/CT
Case report
Essais cliniques
EMBASE
MEDLINE
CASE REPORT/CT
CASE REPORTS/DT
CLINICAL TRIAL+NT/CT
CONTROLLED CLINICAL TRIAL/CT
RANDOMIZED CONTROLLED TRIAL/CT
MULTICENTER STUDY/CT
PHASE 1 CLINICAL TRIAL/CT
PHASE 2 CLINICAL TRIAL/CT
PHASE 3 CLINICAL TRIAL/CT
PHASE 4 CLINICAL TRIAL/CT
CLINICAL TRIAL/DT
CLINICAL TRIAL PHASE I/DT
CLINICAL TRIAL PHASE II/DT
CLINICAL TRIAL PHASE III/DT
CLINICAL TRIAL PHASE IV/DT
CLINICAL TRIALS AS TOPIC+NT/CT
is used for general design,
methodology, economics, etc. of clinical trials
Thesauri dans BIOSIS
• BIOSIS offre 4 thesauri :




Controlled Terms (/CT)
Concept Codes (/CC)
Geographical Terms (/GT)
Organism Thesaurus (/ORGN)
AN
DN
TI
AU
CS
SO
DT
LA
ED
CC
2012:248381 BIOSIS
PREV201200248381
THE EFFECTS OF SIMVASTATIN ON HUMAN AIRWAY EPITHELIAL CELL VIABILITY AND
MORPHOLOGY.
Zeki, Amir A. [Reprint Author]; Ghavami, Saeid; Halayko, Andrew; Wu, Reen
Univ Calif, Davis Sch Med, Sacramento, CA USA
Journal of Investigative Medicine, (MAR 2012) Vol. 60, No. 3, pp. 620.
http://journals.lww.com/jinvestigativemed/pages/default.aspx
Meeting Info.: Eastern Regional Meeting of the
American-Federation-for-Medical-Research. Washington, DC, USA. April 17
-18, 2012. Amer Federat Med Res, Eastern Reg.
ISSN: 1081-5589. E-ISSN: 1708-8267.
Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Concept Codes décrivent les
English
Entered STN: 21 Mar 2012
concepts généraux.
Last Updated on STN: 21 Mar 2012
General biology - Symposia, transactions and proceedings
00520
Cytology - Animal
02506
Cytology - Human
02508
Biochemistry studies - General
10060
Enzymes - General and comparative studies: coenzymes
10802
Pathology - Therapy
12512
Respiratory system - Physiology and biochemistry
16004
Pharmacology - General
22002
Pharmacology - Clinical pharmacology
22005
Pharmacology - Cardiovascular system
22010
IT
IT
IT
Major Concepts
Pharmacology; Biochemistry and Molecular Biophysics; Respiratory
System (Respiration)
Parts, Structures, & Systems of Organisms
airway epithelial cell: respiratory system
Chemicals & Biochemicals
mevalonate; HMG-CoA reductase; statin; Trypan blue; simvastatin:
enzyme inhibitor-drug, antiatherogenic-drug, HMG CoA reductase
inhibitor-drug, antihyperlipoproteinemic-drug, cardiovascular-drug,
Controlled Terms pour une
pharmacodynamics, efficacy, dosage
indexation précise.
ORGN Classifier
Hominidae
86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
human (common)
HBE1 cell line (cell_line): human bronchial epithelial cells
NHBE cell line (cell_line): human normal bronchial epithelial cells
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates, Vertebrates
RN
150-97-0 (mevalonate)
291541-96-3 (HMG-CoA reductase)
79902-63-9 (statin)
72-57-1 (Trypan blue)
79902-63-9 (simvastatin)
Organismes
Derwent Drug File : thésaurus CT
=> FILE DDFU
=> E SIMVASTATIN+ALL/CT
E1
0
BT2 HEMATOLOGIC/CARDIOVASCULAR AGENTS/CT
E2
31610
BT1 ANTIARTERIOSCLEROTICS/CT
E3
0
BT2 ENZYMES/INHIBITORS/CT
E4
0
BT2 HEMATOLOGIC/CARDIOVASCULAR AGENTS/CT
E5
12586
BT1 HMG-COA-REDUCTASE-INHIBITORS/CT
E6
6197
--> SIMVASTATIN/CT
E7
4
UF
mk-733/CT
E8
32
UF
synvinolin/CT
E9
32
OLD SYNVINOLIN/CT
TN
E10
5
TN
SINVACOR/CT
E11
174
TN
ZOCOR/CT
********** END **********
: trade names
=> S E6-E11
L1
6197
4
32
32
5
174
6232
SIMVASTATIN/CT
MK-733/CT
SYNVINOLIN/CT
SYNVINOLIN/CT
SINVACOR/CT
ZOCOR/CT
(SIMVASTATIN/CT OR MK-733/CT OR SYNVINOLIN/CT OR SYNVINOLIN/CT
OR SINVACOR/CT OR ZOCOR/CT)
AN
TI
AU
CS
LO
SO
AV
LA
DT
FA
FS
SH
CC
2012-09145 DDFU
M S
Boceprevir and telaprevir for the treatment of chronic
hepatitis C: safety management in clinical practice.
Hezode C
INSERM; Univ.Val-deMarne
Creteil, France
Liver Int. (32, Suppl.1 Spec.IssueSI, 32-8, 2012) 3 Fig. 4
Tab. 27 Ref.
ISSN: 1478-3223
Univ Paris Est, Hop Henri Mondor, 51 Ave Marechal Lattre
Tassigny, Creteil, France, F-94010. (Hezode C, e-mail:
[email protected]).
English
Journal
AB; LA; CT
Literature
M Microbiology
SH : Subject Heading
S Adverse Effects
35 Adverse Reactions
CC : Classification Code
41 Virucides
66 Drug Interactions
69 Reviews
CT
ANEMIA *AE; DERMATOLOGY *AE; RASH *AE; IN-VIVO *FT; CASES
*FT; REVIEW*FT
[01] BOCEPREVIR *AE; DR0144241 *RN;
HEPATITIS-C-VIRUS-NS3-PROTEASE-INHIBITORS *FT;
HEPATITIS-C-VIRUS-PROTEASE-INHIBITORS *FT;
PEPTIDE-HYDROLASE-INHIBITORS *FT; VIRUCIDES *FT; MAIN-TOPIC
*FT; AE
[02] TELAPREVIR *AE; DR0124498 *RN;
HEPATITIS-C-VIRUS-NS3-PROTEASE-INHIBITORS *FT;
PEPTIDE-HYDROLASE-INHIBITORS *FT; VIRUCIDES *FT; MAIN-TOPIC
*FT; AE*FT
[03] ALFUZOSIN *AE; AMIODARONE *AE; AMIODARONE *DI; BEPRIDIL *AE;
BEPRIDIL *DI; QUINIDINE *AE; QUINIDINE *DI; CARBAMAZEPINE
*AE; PHENOBARBITAL*AE; PHENYTOIN *AE; ASTEMIZOLE *AE;
TERFENADINE *AE; LUMEFANTRINE *AE;
HALOFANTRINE *AE; RIFAMPICIN *AE; MIDAZOLAM *AE; TRIAZOLAM
*AE; CISAPRIDE *AE; DIHYDROERGOTAMINE *AE; ERGOMETRINE *AE;
ERGOTAMINE *AE; METHYLERGOMETRINE *AE; ATORVASTATIN *AE;
ATORVASTATIN *DI; SIMVASTATIN *AE; SIMVASTATIN *DI;
LOVASTATIN *AE; SILDENAFIL *AE; TADALAFIL *AE; LIDOCAINE *DI;
AE *FT; DI *FT
L’indexation DDFU comprend
des qualificatifs (roles)
Derwent Drug File : 9 qualificatifs
Role
---*AE
Definition
---------------Adverse-Effect
Description/Notes
---------------------------------------use for drugs showing adverse side
effects or toxicity, or for diseases produced by drugs
*DI
Drug Interaction
use for drugs influencing or being influenced by other drugs
*DM
Drug Metabolism
use only with drug controlled terms
*OC
Other Context
used for diseases which are not being treated and are
not occurring as an adverse effect, and for drugs where
the context is other than one covered by the other drug
roles (e.g. analysis, synthesis, pharmaceutics, isolation).
*PH
Pharmacology
use only with drug controlled terms
*RC
Reference Compound use for comparison drugs, pharmacological tools and reagents
*RN
Registry Name
Derwent Drug Registry Name
*TR
Treatment
use for drugs in treatment and for diseases being treated; applicable to
humans only
*FT
Further Term
use with controlled terms other than drug names, drug synonyms,
disease names or disease higher terms (e.g. endogenous compounds,
organs, animals, techniques, activity terms, drug classification terms)
=> E SIMVASTATIN/CT
E#
FREQUENCY
AT
TERM
-------------E1
1
SIMVASTAR/CT
E2
1
SIMVASTAR *PH/CT
E3
6197
11 --> SIMVASTATIN/CT
E4
1208
SIMVASTATIN *AE/CT
E5
572
SIMVASTATIN *DI/CT
E6
292
SIMVASTATIN *DM/CT
E7
105
SIMVASTATIN *OC/CT
E8
1947
SIMVASTATIN *PH/CT
E9
256
SIMVASTATIN *RC/CT
E10
3715
SIMVASTATIN *TR/CT
E11
5
SIMVASTATIN SODIUM/CT
E12
5
SIMVASTATIN SODIUM *PH/CT
=> S E4-E5
L1
1598 ("SIMVASTATIN *AE"/CT OR "SIMVASTATIN *DI"/CT)
=> D TI HIT
L1
ANSWER 2 OF 1598 DDFU COPYRIGHT 2012 THOMSON REUTERS on STN
TI
Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach
to Cardiovascular Risk Reduction.
CT [02] TORCETRAPIB *TR; TORCETRAPIB *AE; SIMVASTATIN *TR;
SIMVASTATIN *DI; DILTIAZEM *DI; KETOCONAZOLE *DI; TR *FT; AE
ADISNEWS
3 Newsletters :
• Reactions (alerts to adverse drug reactions from all
adverse drug events reported in the world's biomedical
literature – 78000 réf.)
• Inpharma (alerts to drugs and drug therapy – 40000 réf.)
• Pharmacoeconomics & Outcomes News (health
economics news – 20000 réf.)
• Limitation à la newsletter “Reactions”
=> S SIMVASTATIN AND REACTIONS/FS
L1
598 SIMVASTATIN AND REACTIONS/FS
FS : File Segment
=> D ALL
L3
AN
ED
DN
TI
SO
DT
WC
TX
ANSWER 1 OF 598 ADISNEWS COPYRIGHT (C) 2013 Adis Data Information on STN
2012:7951 ADISNEWS
Entered STN: 29 Nov 2012
Last Updated on STN: 5 Dec 2012
01149954-803080649
ADR news: Amitriptyline/carbamazepine. SIADH treated with urea: case
report. Serious.
REACTIONS 29 Nov 2012 ISSN: 0114-9954
(MIX)
267
A 64-year-old man developed syndrome of inappropriate antidiuretic hormone
secretion (SIADH) during treatment with amitriptyline and carbamazepine
[routes and dosages not stated] for diabetic neuropathy; he was
subsequently treated with urea.
The man had a history of type 2 diabetes mellitus, dyslipidaemia,
hypothyroidism, hypertension, diabetic polyneuropathy and incipient
diabetic nephropathy; he had been receiving repaglinide, insulin glargine,
simvastatin, telmisartan, aspirin and, for the past 2 months,
amitriptyline and carbamazepine. He presented with constipation and
laboratory tests revealed the following: glycaemia, 129 mg/dL; plasma
potassium, 4.6 mEq/L; plasma sodium, 105 mEq/L; plasma chloride, 72 mEq/L;
pH, 7.45; bases, 26 mmol/L; plasma osmolality, 230 mOsm/kg; urinary
sodium, 48 mEq/L; and urine osmolality, 301 mOsm/L. A chest x-ray revealed
mild bilateral pleural effusion. He was diagnosed with severe chronic
hyponatraemia, plasma hyposmolality and normal extracellular fluid,
consistent with SIADH.
RE
CT
RN
Amitriptyline and carbamazepine were withdrawn and the man received
furosemide, IV hypertonic sodium solution and fluid restriction. His
plasma sodium level increased to 126 mEq/L 36 hours later. Vasopressin
levels were normal. However, 24 hours after the hypertonic sodium solution
was stopped, his natraemia decreased to 10 mEq/L; his infusion was
restarted along with oral urea 0.5 mg/kg/d. He tolerated the urea well and
was later discharged from hospital with natraemia of 134 mEq/L on urea
alone. Clinical history, tumour markers, and images of the CNS, chest and
abdomen excluded neoplasms and other disorders such as renal, adrenal or
thyroid failure, so he was diagnosed with SIADH due to amitriptyline and
carbamazepine [patient outcome not clearly stated].
Author Comment: The patient was diagnosed with SIADH secondary to drugs
(amitriptyline and carbamazepine).
(1) Varsavsky, M.; Quesada Charneco, M.; Rozas Moreno, P. Urea as
therapeutic option for the treatment of the syndrome of inappropriate
antidiuretic hormone secretion (SIADH). Medicina Clinica 2011, V137,
P237-8 (Spanish, Case report (Spain))
Amitriptyline, serious adverse-reactions; Carbamazepine, serious
adverse-reactions; Inappropriate-antidiuretic-hormone-secretion,
drug-induced
50-48-6 (AMITRIPTYLINE)
50-78-2 (ASPIRIN)
54-31-9 (FUROSEMIDE)
11000-17-2 (ANTIDIURETIC HORMONE)
11000-17-2 (VASOPRESSIN)
79902-63-9 (SIMVASTATIN)
135062-02-1 (REPAGLINIDE)
144701-48-4 (TELMISARTAN)
160337-95-1 (INSULIN GLARGINE)
=> E SIMVASTATIN/CT
E1
E2
E3
E4
E5
E6
E7
E8
E9
E10
E11
E12
1
SIMETHICONE, SERIOUS DRUG-INTERACTIONS/CT
7
SIMETHICONE, THERAPEUTIC-USE/CT
0 --> SIMVASTATIN/CT
132
SIMVASTATIN, ADVERSE-REACTIONS/CT
31
SIMVASTATIN, DRUG-INTERACTIONS/CT
1
SIMVASTATIN, GENERAL/CT
61
SIMVASTATIN, PHARMACODYNAMICS/CT
7
SIMVASTATIN, PHARMACOKINETICS/CT
95
SIMVASTATIN, SERIOUS ADVERSE-REACTIONS/CT
79
SIMVASTATIN, SERIOUS DRUG-INTERACTIONS/CT
1
SIMVASTATIN, SERIOUS OVERDOSE/CT
325
SIMVASTATIN, THERAPEUTIC-USE/CT
=> S E4-E5 OR E9-E11
L2
132
31
95
79
1
334
"SIMVASTATIN, ADVERSE-REACTIONS"/CT
"SIMVASTATIN, DRUG-INTERACTIONS"/CT
"SIMVASTATIN, SERIOUS ADVERSE-REACTIONS"/CT
"SIMVASTATIN, SERIOUS DRUG-INTERACTIONS"/CT
"SIMVASTATIN, SERIOUS OVERDOSE"/CT
("SIMVASTATIN, ADVERSE-REACTIONS"/CT OR "SIMVASTATIN, DRUG-INTER
ACTIONS"/CT) OR ("SIMVASTATIN, SERIOUS ADVERSE-REACTIONS"/CT OR
"SIMVASTATIN, SERIOUS DRUG-INTERACTIONS"/CT OR "SIMVASTATIN,
SERIOUS OVERDOSE"/CT)
La recherche multifichiers
=> FILE MEDLINE
=> S SIMVASTATIN/CT (L) (AE OR PO OR TO OR DI) AND 2012-2013/PY
L1
38 SIMVASTATIN/CT (L) (AE OR PO OR TO OR DI) AND 2012-2013/PY
=> S (SIMVASTATIN OR ZOCOR)(5A)(ADVERSE(W)(REACTION OR EFFECT OR EVENT) OR
?TOXIC?) AND NONINDEXED/FS AND 2012-2013/PY
L2
6 (SIMVASTATIN OR ZOCOR)(5A)(ADVERSE(W)(REACTION OR EFFECT OR
EVENT) OR ?TOXIC?) AND NONINDEXED/FS AND 2012-2013/PY
=> FILE EMBASE
=> S SIMVASTATIN/CT (L) (AE OR TO OR DI) AND 2012-2013/PY
L3
239 SIMVASTATIN/CT (L) (AE OR TO OR DI)/CT AND 2012-2013/PY
=> FILE DDFU
=> S (SIMVASTATIN *AE/CT OR SIMVASTATIN *DI/CT) AND 2012-2013/PY
L4
81 (SIMVASTATIN *AE/CT OR SIMVASTATIN *DI/CT) AND 2012-2013/PY
=> FILE PASCAL SCISEARCH
=> S (SIMVASTATIN OR ZOCOR)(5A)(ADVERSE(W)(REACTION OR EFFECT OR EVENT) OR
?TOXIC?) AND 2012-2013/PY
L5
18 (SIMVASTATIN OR ZOCOR)(5A)(ADVERSE(W)(REACTION OR EFFECT OR
EVENT) OR ?TOXIC?) AND 2012-2013/PY
L’élimination des doublons
=> DUP REM L1 L2 L3 L4 L5
DUPlicate
REMove
FILES 'MEDLINE, EMBASE, DDFU, PASCAL, SCISEARCH' ENTERED
AT 13:51:47
ON 27 MAR
5 FILES IN THE FILE LIST
L6
325 DUP REM L1 L2 L3 L4 L7 (57 DUPLICATES REMOVED)
ANSWERS '1-44' FROM FILE MEDLINE
ANSWERS '45-254' FROM FILE EMBASE
ANSWERS '255-318' FROM FILE DDFU
ANSWER '319' FROM FILE PASCAL
ANSWERS '320-325' FROM FILE SCISEARCH
=> D TI HIT FROM EACH
L6
TI
SO
CT
ANSWER 1 OF 325
MEDLINE on STN
DUPLICATE 1
No treatment is often the best treatment.
BMJ (Clinical research ed.), (2012) Vol. 345, pp. e7458. Electronic
Publication Date: 19 Nov 2012
Journal code: 8900488. E-ISSN: 1756-1833. L-ISSN: 0959-535X.
Check Tags: Male
Humans
*Hydroxymethylglutaryl-CoA Reductase Inhibitors: AE, adverse effects
*Musculoskeletal Pain: CI, chemically induced
*Simvastatin: AE, adverse effects
L6
TI
SO
CT
L8
TI
PY
CT
ANSWER 45 OF 325 EMBASE COPYRIGHT (c) 2013 Elsevier B.V. All rights
reserved on STN
DUPLICATE 6
Adverse drug reactions caused by drug-drug interactions in elderly
outpatients: A prospective cohort study.
European Journal of Clinical Pharmacology, (December 2012) Vol. 68, No.
12, pp. 1667-1676.
Refs: 49
ISSN: 0031-6970; E-ISSN: 1432-1041 CODEN: EJCPAS
Medical Descriptors:
adult
age distribution
simvastatin: AE, adverse drug reaction
simvastatin: CB, drug combination
ANSWER 255 OF 325 DDFU COPYRIGHT 2013 THOMSON REUTERS on STN
Effect of ezetimibe on the prevalence of cholelithiasis.
2012
[02] SIMVASTATIN *AE; SYNVINOLI *RN; ANTIARTERIOSCLEROTICS *FT;
HMG-COA-REDUCTASE-INHIBITORS *FT; AE *FT
L8
TIEN
SO
AB
L8
TI
SO
ANSWER 319 OF 325 PASCAL COPYRIGHT 2013 INIST-CNRS. ALL RIGHTS
RESERVED. on STN
Streptococcal M1 Protein Triggers Farnesyltransferase-Dependent
Formation of CXC Chemokines in Alveolar Macrophages and Neutrophil
Infiltration of the Lungs
Infection and immunity, (2012), 80(11), 3952-3959, 42 refs.
ISSN: 0019-9567 CODEN: INFIBR
The M1 serotype of Streptococcus pyogenes plays an important role in
streptococcal toxic shock syndrome. Simvastatin, a
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has
ANSWER 320 OF 325 SCISEARCH COPYRIGHT (c) 2013 The Thomson Corporation
on STN
HIGH DOSE ATORVASTATIN ASSOCIATED WITH INCREASED RISK OF SIGNIFICANT
HEPATOTOXICITY IN COMPARISON TO SIMVASTATIN: A RETROSPECTIVE COHORT
STUDY USING THE UK GENERAL PRACTICE RESEARCH DATABASE
JOURNAL OF HEPATOLOGY, (APR 2012) Vol. 56, Supp. [2], pp. S528-S528. MA
1343.
ISSN: 0168-8278.
Mise en place d’alertes
• Sélection des banques de données
– Mono ou multifichiers
• Stratégie
– Unique ou spécifique à chaque banque de données
• Suivi manuel ou automatisé
– Codes de mise à jour (UP ou ED)
• Elimination des doublons
• Fréquence
• Réception des références
50
Fréquences de mise à jour
Fréquences des profils automatisés
Update frequencies
Run frequency options
(automatic SDIs)
EMBASE
EMBAL (in-process)
daily
daily
weekly or biweekly
daily, weekly, biweekly
MEDLINE
5 times a week
every update , weekly or
monthly
BIOSIS
weekly
• Update codes (ED, UP ….)
DDFU
weekly
weekly or biweekly
ADISNEWS
daily
daily, weekly, monthly
PASCAL
weekly
weekly
weekly, monthly
LES ALERTES
• Suivi manuel : codes de mise à jour
• Entry date (/ED)
• Update (/UP)
 nouvelles références
 nouvelles références + mises à jour
=> FILE MEDLINE
=> S RASAGILINE AND ED>20130100
L1
3 RASAGILINE AND ED>20130100
L1
TI
ANSWER 1 OF 3
MEDLINE on STN
Comparative single-dose pharmacokinetics of rasagiline in minipigs after
oral dosing or transdermal administration via a newly developed patch.
SO
Xenobiotica; the fate of foreign compounds in biological systems, (2013
Jan 23) . Electronic Publication Date: 23 Jan 2013
ED
Entered STN: 29 Jan 2013
Last Updated on STN: 29 Jan 2013
=> S RASAGILINE AND UP>20130100
L2
18 RASAGILINE AND UP>20130100
L2
TI
SO
ANSWER 4 OF 18
MEDLINE on STN
Drug-printing by flexographic printing technology-A new manufacturing
process for orodispersible films.
International journal of pharmaceutics, (2013 Jan 30) Vol. 441, No. 1-2,
pp. 818-25. Electronic Publication Date: 21 Dec 2012
Entered STN: 26 Dec 2012
Last Updated on STN: 29 Jan 2013
LES ALERTES
• Suivi automatisé : Commande SDI ou ALERT
– Monofichier
=> SDI STANDARD
– Multifichier
=> SDI STANDARD MFILE PACKAGE
• Hebdomadaire :
• Mensuel :
réception chaque mardi
réception le dernier jour du mois
• Elimination automatique des doublons
• les références sont conservées pendant un an
Mise en place d’une alerte hebdomadaire dans
Medline, Embase, Embal et Pascal
=> FILE MEDLINE EMBASE EMBAL PASCAL
FILES 'MEDLINE, EMBASE, EMBAL, PASCAL' ENTERED AT 13:30:49 ON 04 FEB
2013
4 FILES IN THE FILE LIST
=> S ROPINIROLE OR PARKIROP OR REQUIP OR ROPARK OR ROPITAR
OR SKF 101468# OR SKF101468#
L1
4519 ROPINIROLE OR PARKIROP OR REQUIP OR ROPARK OR ROPITAR
OR SKF 101468# OR SKF101468#
Mise en place d’une alerte hebdomadaire dans
Medline, Embase, Embal et Pascal
=> SDI STANDARD MFILE PACKAGE
MULTIFILE SDI GENERAL PARAMETERS
-------------------------------ENTER TITLE (NONE):SUIVI ROPINIROLE
ENTER COST CENTER (NONE) OR NONE:.
ENTER EMAIL ID (126K):[email protected]
[email protected]
ENTER PRINT FORMAT (FILEDEFAULT) OR ?:BIB ABS
ENTER FREQUENCY OF DELIVERY (MONTHLY) OR WEEKLY:WEEKLY
----------------------------------------------MULTIFILE SDI FILE SPECIFIC PARAMETERS: MEDLINE
------ENTER QUERY L# FOR MULTIFILE SDI REQUEST OR END:L1
ENTER UPDATE FIELD CODE (ED), UP OR ?:UP
----------------------------------------------MULTIFILE SDI FILE SPECIFIC PARAMETERS: EMBASE
-----ENTER QUERY L# FOR MULTIFILE SDI REQUEST OR END:L1
ENTER UPDATE FIELD CODE (ED), UP, EDAL, UPAL OR ?:UP
----------------------------------------------MULTIFILE SDI FILE SPECIFIC PARAMETERS: EMBAL
----ENTER QUERY L# FOR MULTIFILE SDI REQUEST OR END:L1
ENTER UPDATE FIELD CODE (ED), UP OR ?:UP
----------------------------------------------MULTIFILE SDI FILE SPECIFIC PARAMETERS: PASCAL
ENTER QUERY L# FOR MULTIFILE SDI REQUEST OR END:L1
MULTIFILE SDI HAS
QUERY L1 HAS BEEN
QUERY L2 HAS BEEN
QUERY L3 HAS BEEN
QUERY L4 HAS BEEN
BEEN SAVED AS SDI REQUEST 'AA083/S'
SAVED AS SDI REQUEST 'AA084/S' FOR FILE
SAVED AS SDI REQUEST 'AA085/S' FOR FILE
SAVED AS SDI REQUEST 'AA086/S' FOR FILE
SAVED AS SDI REQUEST 'AA087/S' FOR FILE
MEDLINE
EMBASE
EMBAL
PASCAL
Réception par voie électronique
• La première fois, s’enregistrer dans le fichier STNMAIL
=> FILE STNMAIL ; => SET MAILID
•
ENTER EMAIL ID (126K):[email protected]
– Réception d’un email contenant des liens RTF, PDF, HTML, ASCII
•
ENTER EMAIL ID (126K):[email protected]
– Les références sont incluses dans le corps du message
Modification des paramètres d’une alerte
• Avec le logiciel STN Express,
Via le menu Discover  Sdi  Edit an alert
Modification des paramètres d’une alerte
• Avec le langage de commande
=> SDI EDIT MFILE AA083/S
PARAMETER
SETTING
--------------------------- ---------------------------------------SDI Name and Creation Date AA083/S
04 FEB 2013
SDI MFILE REQUEST
1 Title
SUIVI ROPINIROLE
2 Cost Center
NONE
3 Method of Delivery
EMAIL
4 Email ID(s)
[email protected]
5 Max Hits Delivered per File 100
6 Print Format
BIB ABS
7 SDI Sort Parameters
NOT SPECIFIED
8 Archive Answers
0
9 Redistribute Answers
0
10 Notification
NO
11 Highlighting
YES
12 Send SDI with No Answers
YES
13 Duplicate Elimination
NO
14 Delivery Method
PACKAGE (WEEKLY)
15 Display Query with Results YES
16 Display Patent Currency
NO
17 SDI Expiration Date
NOT SPECIFIED
ENTER LINE NUMBERS FOR CHANGE, NEXT, END, OR (?):13
PARAMETER
SETTING
--------------------------- ---------------------------------------SDI Name and Creation Date AA083/S
04 FEB 2013
SDI MFILE REQUEST
1 Title
SUIVI ROPINIROLE
2 Cost Center
NONE
3 Method of Delivery
EMAIL
4 Email ID(s)
[email protected]
5 Max Hits Delivered per File 100
6 Print Format
BIB ABS
7 SDI Sort Parameters
NOT SPECIFIED
8 Archive Answers
0
9 Redistribute Answers
0
10 Notification
NO
11 Highlighting
YES
12 Send SDI with No Answers
YES
13 Duplicate Elimination
14 Delivery Method
15 File Preference for DUP
YES
PACKAGE (WEEKLY)
1) MEDLINE
2) EMBASE
3) EMBAL
4) PASCAL
16 Display Query with Results YES
17 Display Patent Currency
NO
18 SDI Expiration Date
NOT SPECIFIED
ENTER LINE NUMBERS FOR CHANGE, NEXT, END, OR (?):END
SAVE THE CHANGES? (Y)/N:Y
SDI REQUEST 'AA083/S' HAS BEEN EDITED
Autres champs de recherche
AU
Author
Auteur
S CALLSTROM M?/AU
S TEVA/CS
CS
Corporate Source
Organisme d’affiliation
S LODZ UNIVERSITY/CS
LA
Language
Langue originale
S L1 AND FRENCH/LA
S L1 AND 2013/PY
PY
Publication Year
Année de publication
publications de 2013
S L1 AND PY>2005
publications postérieures à 2005
DT
Document Type
Type de document
S GENERAL REVIEW/DT
JT
Journal Title
Titre du journal complet
S JOURNAL OF UROLOGY/JT
Unitermes
S (LYSOSOMAL DISEASE AND
SAN DIEGO)/SO
SO
Source
Merci de votre attention
www.capadoc.com
www.stn-international.com
www.cas.org